Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

(2016) Michele Ceccarelli et al.   CELL

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing

(2014) Betty Y. S. Kim et al.   JOURNAL OF NEURO-ONCOLOGY

Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status

(2014) Anne L. Baldock et al.   NEURO-ONCOLOGY

Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection

(2014) K. R. Noll et al.   NEURO-ONCOLOGY

Diffuse low-grade gliomas and neuroplasticity

(2014) H. Duffau   Diagnostic and Interventional Imaging

Subgrouping of gliomas on the basis of genetic profiles

(2013) Yuichi Hirose et al.   Brain Tumor Pathology

Isocitrate dehydrogenase 1: what it means to the neurosurgeon

(2013) Tiffany R. Hodges et al.   JOURNAL OF NEUROSURGERY

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma

(2013) Chunzhi Zhang et al.   NEURO-ONCOLOGY

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

(2013) Jason Beiko et al.   NEURO-ONCOLOGY

IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis

(2013) Hong-Bin Cheng et al.   TUMOR BIOLOGY

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial

(2012) Monika E. Hegi et al.   ACTA NEUROPATHOLOGICA

The Definition of Primary and Secondary Glioblastoma

(2012) H. Ohgaki et al.   CLINICAL CANCER RESEARCH

Moving toward molecular classification of diffuse gliomas in adults

(2012) B. J. Theeler et al.   NEUROLOGY

Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas

(2011) Michael Weller et al.   GLIA

Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin

(2011) Albert Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence Trends in the Anatomic Location of Primary Malignant Brain Tumors in the United States: 1992–2006

(2011) Gabriel Zada et al.   World Neurosurgery

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism

(2010) Z. J. Reitman et al.   JNCI-Journal of the National Cancer Institute

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

(2010) Nanne K Kloosterhof et al.   LANCET ONCOLOGY

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology

(2009) L. A.M. Gravendeel et al.   CANCER RESEARCH

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

(2009) Koichi Ichimura et al.   NEURO-ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE